{"schema_version":"secwatch.filing_event.v1","accession":"0001701478-26-000029","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2026-05-13T00:09:52+00:00","discovered_at":"2026-05-13T10:05:00.314314+00:00","generated_at":"2026-05-13T10:05:47.653264+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Azitra Q1 net loss $3.9M; adds MD Anderson for ATR-04 trial","bullets":["Net loss $3.9M ($1.6M R&D, $2.4M G&A); cash $10.1M at March 31, 2026.","Added MD Anderson Cancer Center as clinical site for Phase 1/2 trial of ATR-04 targeting EGFRi-associated rash.","Launched cosmeceutical initiative using filaggrin protein/peptide technologies for fine lines and wrinkles.","Secured new U.S. patent for ATR-12 (Netherton syndrome); Phase 1b topline data expected H2 2026.","Private placement financing of up to ~$10.5M (up to ~$20.9M if warrants exercised)."],"urls":{"canonical":"https://secwatch.observer/filing/0001701478-26-000029","json":"https://secwatch.observer/filing/0001701478-26-000029.json","markdown":"https://secwatch.observer/filing/0001701478-26-000029.md","text":"https://secwatch.observer/filing/0001701478-26-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000170147826000029/0001701478-26-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000170147826000029/aztr-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T10:05:47.653264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8a9b54bf42dd577e56f0ed375e89b113564da67","claim":"Azitra, Inc. reported the quarter ended March 31, 2026 results: net income $3.9 million.","evidence_excerpt":"Net Loss was $3.9 million for the quarter ended March 31, 2026, compared to $3.1 million for the comparable period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701478/000170147826000029/0001701478-26-000029-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"$3.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}